AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Off Shifts Pipeline To First Tracks Biotherapeutics GSK: 'Strong Buy' On Mo-Rez Oncology Expansion Potential AnaptysBio: Upside Constrained By Undifferentiated Data, Legal Uncertainties AnaptysBio ...

AnaptysBio Inc. ANAB shares are up on Monday as the company celebrates a favorable ruling from the Delaware Chancery Court ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AnaptysBio, Inc. (ANAB) been one of those stocks this year?

Multiple analysts have issued price targets for $ANAB recently. We have seen 6 analysts offer price targets for $ANAB in the last 6 months, with a median target of ...

Investigational rosnilimab was safe and well-tolerated; however, it did not meet the primary endpoint of the mean change from baseline in the modified Mayo Score (severity of ulcerative colitis, mMS) ...

AnaptysBio has spun off its biopharma pipeline into First Tracks Biotherapeutics, shifting to a royalty-focused, virtual ...

AnaptysBio Inc. (NASDAQ: ANAB) has pushed back against claims that it breached its long-standing licensing deal tied to the cancer drug Jemperli, asking a Delaware court to dismiss what it calls an ...